Literature DB >> 18312532

Biomarkers in exhaled breath condensate indicate presence and severity of cystic fibrosis in children.

Charlotte M H H T Robroeks1, Philippe P R Rosias, Dillys van Vliet, Quirijn Jöbsis, Jan-Bart L Yntema, Hein J L Brackel, Jan G M C Damoiseaux, Gertjan M den Hartog, Will K W H Wodzig, Edward Dompeling.   

Abstract

Chronic airway inflammation is present in cystic fibrosis (CF). Non-invasive inflammometry may be useful in disease management. The aim of the present cross-sectional study was to investigate: (i) the ability of fractional exhaled nitric oxide and inflammatory markers (IM) [exhaled breath condensate (EBC) acidity, nitrite, nitrate, hydrogen peroxide (H(2)O(2)), 8-isoprostane, Th1/Th2 cytokines] to indicate (exacerbations of) CF; and (ii) the ability of these non-invasive IM to indicate CF disease severity. In 98 children (48 CF/50 controls), exhaled nitric oxide was measured using the NIOX, and condensate was collected using a glass condenser. In CF interferon (IFN-gamma) and nitrite concentrations were significantly higher, whereas exhaled nitric oxide levels were significantly lower compared with controls (3.3 +/- 0.3 pg/ml, 2.2 +/- 0.2 microM, 10.0 +/- 1.2 p.p.b. vs. 2.6 +/- 0.2 pg/ml, 1.4 +/- 0.1 microM, 15.4 +/- 1.4 p.p.b. respectively). Using multivariate logistic regression models, the presence of CF was best indicated by 8-isoprostane, nitrite and IFN-gamma [sensitivity 78%, specificity 83%; area under receiver operating characteristic curve (AUC) 0.906, p < 0.001]. An exacerbation of CF was best indicated by 8-isoprostane and nitrite (sensitivity 40%, specificity 97%, AUC curve 0.838, p = 0.009). Most indicative biomarkers of CF severity were exhaled nitric oxide, and condensate acidity (sensitivity 96%, specificity 67%; AUC curve 0.751, p = 0.008). In this cross-sectional study, the combination of different exhaled IM could indicate (exacerbations of) CF, and severity of the disease in children. Longitudinal data are necessary to further confirm the role of these markers for the management of CF in children.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18312532     DOI: 10.1111/j.1399-3038.2007.00693.x

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN: 0905-6157            Impact factor:   6.377


  22 in total

Review 1.  Mapping targetable inflammation and outcomes with cystic fibrosis biomarkers.

Authors:  Olivia Giddings; Charles R Esther
Journal:  Pediatr Pulmonol       Date:  2017-07-17

2.  Oxidative stress and inflammatory markers in the exhaled breath condensate of children with OSA.

Authors:  Georgia Malakasioti; Emmanouel Alexopoulos; Christina Befani; Kalliopi Tanou; Vasiliki Varlami; Dimitrios Ziogas; Panayiotis Liakos; Konstantinos Gourgoulianis; Athanasios G Kaditis
Journal:  Sleep Breath       Date:  2011-08-03       Impact factor: 2.816

Review 3.  Asthma in Cystic Fibrosis: Definitions and Implications of This Overlap Syndrome.

Authors:  Chad R Marion; Manuel Izquierdo; Holly C Hanes; Christopher Barrios
Journal:  Curr Allergy Asthma Rep       Date:  2021-02-09       Impact factor: 4.806

4.  Neonates with cystic fibrosis have a reduced nasal liquid pH; a small pilot study.

Authors:  Mahmoud H Abou Alaiwa; Alison M Beer; Alejandro A Pezzulo; Janice L Launspach; Rebecca A Horan; David A Stoltz; Timothy D Starner; Michael J Welsh; Joseph Zabner
Journal:  J Cyst Fibros       Date:  2014-01-11       Impact factor: 5.482

5.  Evolution of spatial and temporal features of functional brain networks across the lifespan.

Authors:  Shruti G Vij; Jason S Nomi; Dina R Dajani; Lucina Q Uddin
Journal:  Neuroimage       Date:  2018-03-06       Impact factor: 6.556

6.  The effects of ivacaftor on CF fatty acid metabolism: An analysis from the GOAL study.

Authors:  Michael Glenn O'Connor; Adam Seegmiller
Journal:  J Cyst Fibros       Date:  2016-07-26       Impact factor: 5.482

7.  Exhaled breath condensate pH in patients with cystic fibrosis.

Authors:  Balazs Antus; Imre Barta; Eszter Csiszer; Krisztina Kelemen
Journal:  Inflamm Res       Date:  2012-06-16       Impact factor: 4.575

8.  Biomarkers in exhaled breath condensate: a review of collection, processing and analysis.

Authors:  N M Grob; M Aytekin; R A Dweik
Journal:  J Breath Res       Date:  2008-09-08       Impact factor: 3.262

Review 9.  Novel end points for clinical trials in young children with cystic fibrosis.

Authors:  Shannon J Simpson; Lauren S Mott; Charles R Esther; Stephen M Stick; Graham L Hall
Journal:  Expert Rev Respir Med       Date:  2013-06       Impact factor: 3.772

10.  Exhaled nitric oxide measurements in the first 2 years of life: methodological issues, clinical and epidemiological applications.

Authors:  Carmelo Gabriele; Fernando M de Benedictis; Johan C de Jongste
Journal:  Ital J Pediatr       Date:  2009-07-20       Impact factor: 2.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.